Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.

Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which i...

Full description

Bibliographic Details
Main Authors: Li Xie, Thomas Evangelidis, Lei Xie, Philip E Bourne
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-04-01
Series:PLoS Computational Biology
Online Access:http://europepmc.org/articles/PMC3084228?pdf=render
id doaj-5b1e198a6da4490097d5b923716ba8b5
record_format Article
spelling doaj-5b1e198a6da4490097d5b923716ba8b52020-11-24T21:56:05ZengPublic Library of Science (PLoS)PLoS Computational Biology1553-734X1553-73582011-04-0174e100203710.1371/journal.pcbi.1002037Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.Li XieThomas EvangelidisLei XiePhilip E BourneNelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which integrates molecular dynamics simulation and MM/GBSA free energy calculations with ligand binding site comparison and biological network analysis, we identified putative human off-targets of Nelfinavir and analyzed the impact on the associated biological processes. Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis. The computational predictions are supported by kinase activity assays and are consistent with existing experimental and clinical evidence. This finding provides a molecular basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacology agent.http://europepmc.org/articles/PMC3084228?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Li Xie
Thomas Evangelidis
Lei Xie
Philip E Bourne
spellingShingle Li Xie
Thomas Evangelidis
Lei Xie
Philip E Bourne
Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
PLoS Computational Biology
author_facet Li Xie
Thomas Evangelidis
Lei Xie
Philip E Bourne
author_sort Li Xie
title Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
title_short Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
title_full Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
title_fullStr Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
title_full_unstemmed Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
title_sort drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
publisher Public Library of Science (PLoS)
series PLoS Computational Biology
issn 1553-734X
1553-7358
publishDate 2011-04-01
description Nelfinavir is a potent HIV-protease inhibitor with pleiotropic effects in cancer cells. Experimental studies connect its anti-cancer effects to the suppression of the Akt signaling pathway, but the actual molecular targets remain unknown. Using a structural proteome-wide off-target pipeline, which integrates molecular dynamics simulation and MM/GBSA free energy calculations with ligand binding site comparison and biological network analysis, we identified putative human off-targets of Nelfinavir and analyzed the impact on the associated biological processes. Our results suggest that Nelfinavir is able to inhibit multiple members of the protein kinase-like superfamily, which are involved in the regulation of cellular processes vital for carcinogenesis and metastasis. The computational predictions are supported by kinase activity assays and are consistent with existing experimental and clinical evidence. This finding provides a molecular basis to explain the broad-spectrum anti-cancer effect of Nelfinavir and presents opportunities to optimize the drug as a targeted polypharmacology agent.
url http://europepmc.org/articles/PMC3084228?pdf=render
work_keys_str_mv AT lixie drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir
AT thomasevangelidis drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir
AT leixie drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir
AT philipebourne drugdiscoveryusingchemicalsystemsbiologyweakinhibitionofmultiplekinasesmaycontributetotheanticancereffectofnelfinavir
_version_ 1725859647036850176